Genome-wide association studies and multi-omics integrative analysis reveal novel loci and their molecular mechanisms for circulating polyunsaturated, monounsaturated, and saturated fatty acids

Yitang Sun[1], Huifang Xu[1], Kaixiong Ye[1,2,*]

[1]Department of Genetics, University of Georgia, Athens, GA, USA
[2]Institute of Bioinformatics, University of Georgia, Athens, GA, USA

[*] Correspondence: Dr. Kaixiong Ye (Kaixiong.Ye@uga.edu)

Abstract

Background: Dietary and circulating levels of polyunsaturated fatty acids (PUFAs) have been associated with mortality and risks of various diseases. The circulating levels of fatty acids (FAs) exhibit heterogeneity across individuals due to genetic and environmental influences. Although previous genome-wide association studies (GWAS) have identified genetic loci associated with FAs, the biological mechanisms of these genetic associations remain largely unexplored.

Methods: Here, we conducted GWAS to identify additional genetic loci for 19 circulating fatty acid (FA) traits, quantified by nuclear magnetic resonance spectroscopy, in UK Biobank participants of European ancestry (N = 239,268) and five other ancestries (N = 508 – 4,663). We leveraged the GWAS findings to characterize genetic correlations and colocalized regions among FAs, explore sex differences, examine FA loci influenced by lipoprotein metabolism, and apply statistical fine-mapping to pinpoint putative causal variants. The integrative analysis of GWAS and multi-omics quantitative trait loci (QTL) reveals intermediate molecular phenotypes mediating the associations between the genetic loci and FA levels.

Results: Altogether, we identified 215 significant loci for PUFAs-related traits in European participants, 163 loci for monounsaturated fatty acids (MUFAs), and 119 loci for saturated fatty acids (SFAs), including 70 novel loci for PUFAs, 61 for MUFAs, and 54 for SFAs. Of these significant loci, a novel locus for total FAs, omega-6 PUFAs relative to total FAs, and total MUFAs (around genes *GSTT1/2/2B*) overlapped with QTL signals for all six molecular phenotypes examined, including gene expression, protein abundance, DNA methylation, splicing, histone modification, and chromatin accessibility. Across FA traits, 65% of GWAS loci overlapped with QTL signals for at least one molecular phenotype.

23   **Conclusions:** Our study identifies additional novel genetic loci and provides the first evidence

24   uncovering molecular mechanisms underlying FAs-relevant variants. These findings offer insights

25   that could facilitate patient stratification for precision nutrition.

27   **Keywords:** GWAS, polyunsaturated fatty acids, fatty acids, xQTL, multi-omics

Introduction

Polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids (MUFAs), and saturated fatty acids (SFAs) have been implicated in various diseases.[1-3] Evidence from epidemiological and genetic studies indicates that PUFAs, especially omega-3 PUFAs, are associated with reduced risks of various diseases or mortality by modifying metabolism and inflammation.[4-7] Circulating fatty acid (FA) levels are influenced by environmental and genetic factors and characterized by sex- and ancestry-specific patterns.[8-10] Dietary intake, socioeconomic status, physical inactivity, cigarette smoking, and alcohol consumption are common environmental factors that influence FA levels.[11] Although hundreds of genetic loci associated with FAs have been identified by genome-wide association studies (GWAS),[12-37] the biological mechanisms of these genetic associations remain largely unexplored. Moreover, these genetic loci were mainly discovered in the European (EUR) population and were focused on autosomes. Extending GWAS to non-EUR populations and sex chromosomes will offer a comprehensive understanding of the genetic architecture of circulating FAs.

In this study, we performed GWAS for 19 FA traits related to PUFAs, MUFAs, and SFAs to identify more novel genetic loci. We conducted overall and sex-specific GWAS using 250,101 individuals of EUR ancestry and five other ancestries from the UK Biobank (UKB). Leveraging the GWAS summary statistics, we characterized heritability for these FA traits and examined their shared genetic basis with genetic correlation and colocalization analysis. Candidate causal variants were pinpointed with statistical fine-mapping. Finally, we integrated GWAS signals with multi-omics data to identify the mediating molecular phenotypes and provide mechanistic insights into the molecular mechanisms underlying the GWAS signals.

Materials and Methods

Participants

The UKB cohort is a prospective population-based study of ~500,000 participants from across the United Kingdom, aged between 37 and 73 years at recruitment from 2006 to 2010.[38] Of the individuals with both phenotype and genotyping data, we excluded participants who have withdrawn consent, mismatched information between phenotypic and genetic sex, sex chromosome aneuploidy, or are outliers for heterogeneity and missing genotype rate. Genetic ancestry groups have been previously defined in the Pan-ancestry genetic analysis of the UK Biobank (Pan-UKB).[39] Together, we included up to 239,268 participants of EUR ancestry in this study. We also included participants of African (AFR) (N = 3,352), admixed American (AMR) (N = 508), Central/South Asian (CSA) (N = 4,663), East Asian (EAS) (N = 1,445), and Middle Eastern (MID) (N = 865) ancestries. Table S1 provides the overall and sex-stratified characteristics of participants in each ancestry group. This study received ethical approval from the National Health Service North West Centre for Research Ethics Committee, and all participants provided informed consent. Data from the UKB resource were accessed under application number 48818.

Phenotypes – circulating fatty acids (FAs)

Plasma FAs were measured in a randomly selected subset of 274,020 participants by Nightingale Health using nuclear magnetic resonance (NMR) spectroscopy.[40] All FA levels and their ratios were normalized within each ancestry group using the rank-based inverse normal transformation in overall GWAS.[41] This inverse normal transformation was applied separately for males and females to account for sex-specific differences in FA distributions. In total, 20 metabolic measurements were analyzed in the GWAS including total FAs, 5 PUFA absolute concentrations (i.e., PUFAs, omega-3 PUFAs, omega-6 PUFAs, docosahexaenoic acid (DHA), and linoleic acid

(LA)), their relative percentages in total FAs (i.e., PUFAs%, omega-3%, omega-6%, DHA%, and

LA%), the ratio of omega-3 to omega-6 PUFAs (omega-3/omega-6), the ratio of omega-6 to

omega-3 PUFAs (omega-6/omega-3), monounsaturated fatty acids (MUFAs), saturated fatty acids

(SFAs), MUFAs%, SFAs%, PUFAs/MUFAs, PUFAs/SFAs, and degree of unsaturation. Both the

omega-3/omega-6 ratio and omega-6/omega-3 ratio were included in our GWAS due to different

preferences in the field, but they revealed the same genetic loci in opposite effect directions. In

additional analyses, we focused on omega-3/omega-6 and did not include omega-6/omega-3,

resulting in a total of 19 plasma metabolic measurements.

Genotyping and quality control

Full details about genotyping, imputation, and genotype-based quality control (QC) have

been described elsewhere.[42] Briefly, we excluded variants with imputation quality score < 0.3,

minor allele frequency < 0.001, genotype missingness per variant > 0.05, and Hardy-Weinberg

test P-value $< 1 \times 10^{-8}$. We also confirmed that no individuals have genotype missingness > 0.05.

For the non-pseudoautosomal region of the X chromosome (GRCh37; chrX: 2699520-154931044),

males were treated as homozygotes of the reference or effect allele, and coded as 0 or 2,

respectively.

Genome-wide association studies (GWAS)

Overall GWAS were conducted for each ancestry group and followed by sex-stratified

GWAS. We carried out GWAS in participants of EUR ancestry using fastGWA from the GCTA

toolbox (v.1.94.1), which controls for familial relatedness using a sparse genetic relationship

matrix (GRM) with a default threshold of 0.05 based on slightly linkage disequilibrium (LD)-

pruned HapMap3 variants.[43,44] Considering the relatively small sample size for other ancestry

groups (AFR, AMR, CSA, EAS, and MID), the mixed-linear-model association (MLMA) method

was used to perform GWAS using a dense GRM.[45] Additionally, sex-specific GWAS were

conducted for each ancestry group using fastGWA for EUR participants and MLMA for other

ancestry groups, excluding sex as a covariate from all models.

To explore the influences of potential covariates, we performed GWAS in the EUR

ancestry participants using 3 models. In model 1, we included age, sex, age × sex, and the top 10

genetic principal components derived from the Pan-UKB as covariates. Model 2 added additional

covariates, including body mass index, Townsend deprivation index, smoking status, alcohol

status, physical activity, and statin use.[46,47] In model 3, we adjusted for fish oil supplementation

status and lipoprotein lipids including chylomicron, very-low-density lipoprotein (VLDL),

intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL), high-density lipoprotein

(HDL) cholesterols as additional covariates. For GWAS in the non-EUR population, we applied

models 1 and 2.

Identification of novel loci

To identify novel loci, we compared our independent loci to the previously reported FA

loci in the GWAS Catalog and in other relevant publications identified by literature review up until

June 2024.[48] Independent loci were identified in our results or previous GWAS based on genome-

wide significance threshold (*P*-value $< 5 \times 10^{-8}$) and LD-based clumping ($r^2 = 0.1$, window size =

250 kb) using PLINK.[49,50] Independent loci were merged based on proximity (±250 kb). We

annotated the lead variants for their target genes and functional consequences using the Ensemble

GRCh37 Variant Effect Predictor (VEP).[51]

Heritability and genetic correlation analyses

Heritability and genetic correlations were estimated with linkage disequilibrium score

regression (LDSC) in the EUR ancestry subset.[52,53] In-sample LD scores were derived from

.[54] As recommended, we checked for inflation using

the attenuation ratio in the EUR population and genomic inflation factor (λ_{GC}) in other

populations.[55]

Colocalization with FA traits

We performed colocalization analysis with HyPrColoc (v.1.0) to assess whether two or

more FA traits share a putative causal variant.[56] Pairwise and multi-trait colocalization analyses

were conducted for each pair or all FA traits altogether. We used the default priors, including the

probability of a variant being associated with a single trait (prior.1 = 1×10^{-4}) and the conditional

probability of association with an additional trait (prior.c = 0.02). A posterior probability (PP) >

0.8 was considered as evidence for a shared causal variant.

Statistical fine-mapping of GWAS loci

To identify the most plausible causal variants for genome-wide significant loci associated

with each FA trait, we used SuSiE (v.0.12.27).[57] We used the 1 Mb region surrounding the lead

variant of each genetic locus for statistical fine-mapping. We utilized in-sample LD information

to estimate the correlations among SNPs. The 95% credible set identified potential causal variants

based on their PP. Only variants with a PP > 0.8 were reported, with higher PP values closer to 1

indicating more likely to be causal variants.

Gene-based and gene-set analyses

MAGMA v.1.08, implemented in FUMA, was used to perform gene-based and gene set

analyses.[58,59] In the gene-based analysis, 19,665 SNPs were linked to protein-coding genes, and

Bonferroni correction was applied to establish the significance threshold ($P < 0.05/19{,}665 = 2.54$

$\times 10^{-6}$). We determined the enrichment of candidate FA-associated genes in specific biological

pathways, cellular components, or molecular functions. A total of 15,481 gene sets (5,497 curated

gene sets and 9,984 gene ontology terms) obtained from MsigDB were tested, with the Bonferroni-

corrected significance threshold set at $P < 3.23 \times 10^{-6}$.[60]

Omics PlEiotRopic Association (OPERA) analysis

To provide mechanistic interpretations of FA-associated variants, we performed an

integrative analysis of six types of multi-omics quantitative trait loci (QTL) summary statistics

with GWAS signals using the Bayesian method, Omics PlEiotRopic Association (OPERA).[61] First,

we obtained available molecular quantitative trait loci (xQTL) data, including gene expression

QTL (eQTL), protein QTL (pQTL), DNA methylation QTL (mQTL), splicing QTL (sQTL),

histone modification QTL (hQTL), and chromatin accessibility QTL (caQTL). We downloaded

blood *cis*-eQTLs summary statistics generated from the eQTLGen study (N = 31,684).[62] The

plasma pQTL summary statistics were retrieved from the UKB Pharma Proteomics Project (UKB-

PPP) using UKB participants (N = 54,219).[63] The peripheral blood mQTL data were generated by

McRae *et al.* (N = 1,980).[64,65] We derived summary-level sQTL data from whole blood samples in

the Genotype Tissue Expression (GTEx) Project v.8 (N = 670).[66] The H3K27ac and H3K4me1

hQTL in monocytes were generated from the BLUEPRINT project (N = 200).[67] The caQTL data

in lymphoblastoid cell line samples were estimated by Kumasaka *et al.* (N = 100).[68] We included

the molecular phenotypes with at least one xQTL with $P < 5 \times 10^{-8}$ and excluded the major

histocompatibility complex (MHC) region due to its structural complexity. After filtering

molecular phenotypes, we retained 15,785 genes, 2,190 proteins, 94,338 DNA methylation sites,

6,639 RNA splicing events, 18,152 histone marks, and 13,873 chromatin accessibility peaks. The

posterior probability of association (PPA) threshold of 0.9 and the multi-exposure heterogeneity

in dependent instruments (HEIDI) test threshold of 0.01 were used to determine if a GWAS signal

overlaps with the QTL signals for one or multiple molecular phenotypes.

Results

Sample characteristics

The primary GWAS study comprised up to 239,268 individuals of EUR ancestry. GWAS

were also conducted on five additional ancestry groups, including up to 3,352 AFR, 508 AMR,

4,663 CSA, 1,445 EAS, and 865 MID individuals. Among EUR participants, the average age was

57 years and females were more likely to have higher PUFA levels (Table S1). The percentage of

female participants in EUR, AFR, AMR, CSA, EAS, and MID populations was 53.9%, 59.7%,

66.9%, 44.8%, 64.6%, and 41.8%, respectively. Approximately 31.6% of individuals reported

regular use of fish oil supplements and the ratio of omega-3/omega-6 was around 1:8.

Identification of genome-wide significant loci for FAs

We first performed EUR ancestry GWAS for each FA trait using three models, respectively.

Since we are particularly interested in the genetic architecture of FA traits in the category of

PUFAs, we primarily use results in this category as examples throughout this article to demonstrate

our findings. Similar results for FA traits in the categories of MUFAs and SFAs are available in

supplementary materials. Figure 1A shows a Manhattan plot of GWAS for the absolute

concentration of total PUFAs in model 2. Table S2 reports the number of significant loci for each

FA from all GWAS across all models. Using model 2, we identified 122 independent genetic loci

for the category of PUFAs, 124 for MUFAs, and 102 for SFAs; however, only 46, 39, and 38 loci

respectively associated with these categories of FA traits in model 3 (Table S2). (Please elaborate

a bit more. Are all loci in model 3 identified in model 2? If not, how many were identified in model

2? Then, the rest is only significant in model 3.) A total of 92 loci identified in model 2 were no

longer significantly associated with total PUFAs after adjusting for fish oil intake and lipoprotein

lipids in model 3 (Figure 1B). We observed similar effect estimates between models 1 and 2,

whereas model 3 yielded systematically larger effect estimates than those from the other two

models (Figure S1). To further explore the distinction between models 3 and 2, we conducted

GWAS based on model 2 by additionally adjusting for fish oil supplementation in model 2.1 and

for lipoprotein lipids in model 2.2. The differences in GWAS results between model 3 and the

others were attributed to the additional adjustment for lipoprotein lipids (Table S2). For example,

variants in the *LDLR* and *MTTP* genes, known for their strong correlation with lipoprotein

lipids,[69,70] were significant in model 2 but not in model 3.

Regarding SNP-based heritability of FA traits in the EUR population, we found that SNPs

explained 5–19% of the phenotypic variance for all FA traits across all three models (Figure S2A;

Table S3). For instance, the SNP-based heritability estimates for the absolute concentrations of

total PUFAs, MUFAs, and SFAs were 19%, 19%, and 16%, respectively, in model 2. The genomic

inflation factor (λ_{GC}) for all GWAS ranged from 1.07 to 1.29 (Table S4). The attenuation ratio

ranged from 0.03 to 0.18, and the LDSC intercept ranged from 1.01 to 1.12, suggesting that the

genome-wide elevation of association statistics was primarily due to true additive polygenic effects

rather than confounders such as population stratification.

To identify novel loci, we searched the literature and GWAS Catalog to compile known

loci for FAs-related traits, making it the most comprehensive collection to date (Table S5). When

categorizing FA traits into PUFAs-related, MUFAs-related, and SFAs-related, we identified 70,

61, and 54 novel loci among 215, 163, and 119 significant loci, respectively, with model 2 (Table

S6). The numbers of novel loci for each FA trait are provided in Table S7. Compared with all

previously reported FAs-related loci, the top 10 strongest novel loci identified across all FA traits

in model 2 were mapped to candidate genes including *PEPD*, *SBNO1*, *IL1RN*, *INSIG2*, *VIM*, *PGS1*,

ARID5B, *NF1*, *FAM96A*, and *PEX6* (Table S8). We also compared independent loci to those

previously reported in GWAS for the same traits. The novel locus *VEGFA* was associated with

total FAs, LA%, SFAs, PUFAs/SFAs, and the degree of unsaturation in our study, and it was

consistently associated with MUFAs, MUFAs%, and PUFAs/MUFAs in both our and previous

GWAS.[29,32,33,37] Variants in *GCKR* were found to be significantly associated with DHA% for the

first time, consistent with previous GWAS findings for other FA traits.

Additionally, we explored genetic associations on the X-chromosome in both overall and

sex-specific GWAS. Previously, only one GWAS identified FA loci on the X-chromosome.[29] That

GWAS reported two X-chromosomal loci associated with FA traits; however, no significant

variants were identified in our overall GWAS. When evaluating males separately, one significant

association with omega-3% was found on the X-chromosome.

Sex-specific FA GWAS

We then stratified the total sample by sex to perform sex-specific GWAS separately for

128,922 females and 110,346 males in the EUR population. Approximately 4.2% of the significant

loci from sex-specific GWAS were not identified in the overall GWAS (Table S7). The SNP-based

heritability ranged from 5% to 21% in females and 4% to 20% in males, and there was no evidence

of genomic inflation (Figures S2B and S2C; Table S3). In model 2, we identified 128 independent

loci associated with PUFAs-related traits in females and 106 loci in males, including 27 and 8

novel loci, respectively, which have not been reported in previous GWAS of PUFAs-related traits

(Table S6). GWAS results for both known and novel loci associated with each FA trait are

provided in Table S9 for females and Table S10 for males. Interestingly, among the three novel

loci associated with PUFAs compared to previous GWAS related to all FA traits, two loci mapped

to *RNU6-1180P* and *KRT18P55* were significant only in females from model 2 (Figure 2). After

accounting for lipoprotein lipids, three additional novel loci for PUFAs, around gene *UNC5CL*,

RP11-328J6.1, and *SIPA1L3*, were identified in females and no novel locus in males was identified

when comparing with all previous FA GWAS in model 3 (Figure S3). In the sex-specific GWAS,

we found that approximately 43% of the genome-wide significant loci identified in models 1 and

2 were not identified in model 3 (Table S7). Notably, one X-chromosomal locus associated with

omega-3%, whose lead SNP is rs147828433, was identified from GWAS using model 2 in males.

Our study is the first to explore loci in sex-specific GWAS and to include the X chromosome.

GWAS for FA traits in individuals of non-EUR ancestries

Across all FA traits, we identified 38 significant loci in ancestry-specific GWAS, of which

23 are novel compared to previous studies in EUR and non-EUR populations (Table S11). The

genomic inflation factor (λ_{GC}) was also reported for each non-EUR ancestry, with average λ_{GC}

values of 0.97, 0.92, 0.99, 0.90, and 0.95 for AFR, AMR, CSA, EAS, and MID, respectively

(Tables S4). In the non-EUR ancestry GWAS, the most significant locus was around *FADS2*,

identified in four ancestry groups except AFR, which is a well-known locus in the EUR population

(Table S11). Among non-EUR populations, CSA had the largest sample size, leading to more loci

being identified compared to other groups, with 1–4 loci in model 1 and 0–2 in model 2 (Table

S2). The GWAS in CSA male participants identified a novel locus *EDN1* associated with total

PUFAs, omega-6 PUFAs, and LA, while this locus did not reach the genome-wide significance in

the EUR population. In addition, variants in *VPS39*, which had not been reported in previous

GWAS, were associated with total PUFAs, omega-6 PUFAs, and LA in both total and male-only

CSA participants.

Genetic correlations among FA traits

We examined genetic correlations (r_g) between FA traits using EUR GWAS summary

statistics from three models (Table S12). Broadly, comparisons of genetic correlations between

models revealed similar estimates for models 1 and 2 but distinct estimates when compared to

model 3, as illustrated in Figure S4. Among the 171 pairs of genetic correlations, 14 pairs that had

significantly negative genetic correlations in models 1 and 2 became significantly positive in

model 3, while four pairs that were significantly positive in models 1 and 2 became significantly

negative in model 3. The strongest correlation was a negative correlation between MUFAs and

PUFAs/MUFAs (r_g = -0.99) observed based on GWAS in both models 1 and 2 (Figures S5 and

S6). Notably, genetic correlations between omega-6 PUFAs and omega-6% were negative in

models 1 (r_g = -0.38) and 2 (r_g = -0.51), but they were positively correlated in model 3 (r_g = 0.34)

after adjustment for lipoprotein lipids (Figure S7). Within omega-3-related traits, genetic

correlations were strong (~0.9) across all three models, with even stronger correlations found in

model 3. We also estimated pairwise phenotypic correlations using Pearson's correlation

coefficient (Table S13). Among significant genetic correlations, all pairs had consistent directions

compared to phenotypic correlations in models 1 and 2, while 83% of pairs had consistent

directions in model 3, suggesting that genetic effects on FA traits were altered after adding

lipoprotein lipids as covariates.

Colocalization of GWAS signals across FA traits

To assess the probability that two FA traits share the same causal variants, we conducted

pairwise colocalization analyses. For the 171 pairs of FA traits, we identified 9–231 colocalized

signals in model 2 and 6–114 in model 3, respectively. We found that pairs with a larger number

of colocalized signals also had stronger genetic correlations (Figure S8). In model 2, potential

causal variants in *DOCK7* (rs2934744), *GCKR* (rs1260326), *ZNF259* (rs964184), *FADS1*

(rs174564), *CPT1A* (rs2229738), *LIPC* (rs2070895), *LIPG* (rs77960347), *LDLR* (rs73015024),

TM6SF2 (rs58542926), and *APOE* (rs7412) showed robust evidence of colocalization, indicating

shared genetic variants for pairs of FA traits (Table S14). After accounting for lipoprotein lipids

in model 3, *FADS1* (rs174564), *CPT1A* (rs2229738), and *BUD13* (chr11:116623213:TA:T) were

identified as colocalized and potentially causal signals for FA traits, with results consistent with

those from model 2 (Table S15). Next, we performed multi-trait colocalization analyses to evaluate

the posterior probability of a shared genetic signal across all FA traits. Overall, 168 and 159

colocalized signals were identified in models 2 and 3, respectively. We identified *GCKR*

(rs1260326), *TRIB1* (rs28601761), *FADS1* (rs174564), *ZNF259* (rs964184), and *APOE* (rs7412)

as shared between multiple FA traits in model 2 (Table S16), and *GCKR* (rs1260326), *TRIB1*

(rs28601761), *FADS1* (rs174564), and *APOE* (rs1065853) from model 3 as shared signals (Table

S17).

Statistical fine-mapping for candidate causal variants

We applied the Bayesian fine-mapping method to identify putative causal variants for FA

traits. We identified 477 unique potential causal variants in model 1, 422 in model 2, and 193 in

model 3 (Table S18). Consistent with colocalization analysis, we confirmed that the genetic

variants at the loci *TRIB1* (rs28601761), *FADS1* (rs174564), *CPT1A* (rs2229738), *LIPC*

(rs2070895), *LIPG* (rs77960347), *LDLR* (rs72658867), *TM6SF2* (rs58542926), and *APOE* (rs7412)

are likely to be causally associated with FA traits. Notably, we found that several loci contain

multiple 95% credible sets, indicating the existence of multiple potential causal variants within

those significant loci. Among the novel loci for FA traits, we found that *ZMIZ1* (rs1782652) was

associated with total FAs, total PUFAs, and omega-3 PUFAs, suggesting that it is a candidate

shared causal variant for these FAs. Additional potential causal variants for novel loci were

identified, including *CPS1* (rs1047891), *ATXN7L1* (rs118061830), *ARID5B* (rs77044968), *SBF2*

(rs12789941), *DGKZ* (rs149903077), *CYFIP1* (rs199854211), *FAM96A* (rs62023393), *MIR122*

(rs41292412), *BCL2* (rs12454712), *INSR* (rs112630404), and *PEPD* (rs62102718).

Gene-based and gene-set analyses

In the genome-wide gene-based association study, 139–541 genes from model 2 and 110–

255 genes from model 3 were found to be significantly associated with 19 FA traits after

Bonferroni correction (Table S19). The top gene across 19 FA traits identified in model 2 was

ALDH1A2 (chr15: 58245622-58790065), which overlaps with another identified gene *LIPC*

(chr15: 58702768-58861151). In the GWAS of the omega-3/omega-6 ratio using model 3, *STH*

was the top gene, which might be related to neurodegenerative diseases such as Alzheimer's

disease.[71] Gene-tissue expression analysis revealed that the liver was the most significantly

enriched tissue, followed by whole blood, kidney, small intestine, spleen, nerve, and adipose tissue

(Tables S20 and 21). Additionally, gene set analysis was performed to investigate potential gene

pathways (Tables S22 and 23). We detected those genes associated with total PUFAs clustered in

biological processes related to lipid homeostasis, secondary alcohol metabolism, organic hydroxy

compound transport, regulations of plasma lipoprotein particle levels and lipid metabolism, and

fatty acid biosynthesis (Figure 3). Fatty acid metabolic and biosynthetic processes were

significantly enriched in the gene set analysis results from GWAS of total PUFAs using model 3

(Figure S9).

OPERA identifies intermediate molecular phenotypes underlying FA-associated loci

To better understand the biological mechanisms of our GWAS findings, we applied

OPERA to explore the overlap of GWAS signals for FA traits and QTL signals for six molecular

phenotypes, including eQTL, pQTL, mQTL, sQTL, hQTL, and caQTL. With a PPA threshold of

0.9 and a P_{HEIDI} threshold of 0.01, we identified 976 FA-associated variants that overlap with QTL

signals for 2,106 unique molecular phenotype measures, including the expression levels of 242

genes, the abundance levels of 60 proteins, the methylation levels at 1,254 DNA sites, the RNA

splicing events at 141 sites, the status of 233 histone marks, and the openness at 176 chromatin

accessibility peaks (Figure 4A and Table S24). Overlaps with xQTL signals were also observed

for a large number of loci after adjusting for lipoprotein lipids in GWAS (Figure 4B and Table

S25). Associations with DNA methylation were more frequent than with other molecular

phenotypes, and these findings were consistent with previous results in other complex traits.[61] The

number of loci associated with eQTL across 19 traits ranged from 7 for the degree of unsaturation

to 68 for PUFAs in model 2, and from 2 to 41 in model 3. Using the pQTL data from UKB-PPP,

we observed that 33 loci for omega-3 PUFAs from models 2 and 3 had the highest number of

significant associations with proteins.

We found that approximately 65% of GWAS loci for 19 FA traits are shared with at least

one molecular phenotype. Among the well-known FA loci, the potential causal variant rs174564

was found to overlap with QTL signals for the expression level of *MYRF* (ENSG00000124920)

and the methylation level at cg01825921. Across FA traits such as total FAs, total PUFAs, omega-

6 PUFAs, and total SFAs, the potential causal variant rs72658867, annotated at the *LDLR* gene,

was associated with histone modification (chr19:11105519-11214483) and chromatin accessibility

(peak 264429). Among the novel loci for omega-6%, rs149903077 (*DGKZ*) was jointly associated

with the nearby gene *NR1H3* (ENSG00000025434), histone modification (chr11:47234446-

47272168), and chromatin accessibility (peak 200213). It was also marginally associated with

methylation (cg01183595).

Notably, all six molecular phenotypes were jointly associated with total FAs, omega-6%,

and total MUFAs at the novel locus *GSTTP1* or nearby genes on chromosome 22 (Figure 5). We

observed that variant rs189660333 was associated with omega-3% jointly with five other types of

molecular phenotypes, except for histone modification. The nearby variants rs12786457 and

rs184864731 were consistently associated with these five phenotypes across GWAS related to

omega-3 PUFAs and the omega-3/omega-6 ratio. Overall, OPERA integrates six types of xQTL

data to offer mechanistic insights into genetic loci and their downstream molecular phenotypes.

Discussion

We performed overall and sex-specific GWAS for 19 FA traits in 250,101 UKB participants of EUR descent and five other ancestry groups, separately. We identified 215, 163, and 119 significant loci for PUFAs-, MUFAs-, and SFAs-related traits, including 70, 61, and 54 novel loci, respectively, in our primary model (i.e., model 2). Adjusting for lipoprotein lipids dramatically reduce the number of GWAS signals. Our analyses of genetic correlations and colocalization revealed the levels of shared genetic basis and specific candidate shared variants across FA traits. Using statistical fine-mapping, we identified 422 putative causal variants across all FA traits. Gene-based and gene-set analyses pinpointed the liver as the most relevant tissue and highlighted biological pathways underlying FA loci. In addition, we integrated GWAS signals with QTL signals for six molecular phenotypes and revealed that approximately 65% of GWAS loci for 19 FA traits are shared with at least one molecular phenotype, offering novel mechanistic insights.

In EUR GWAS, we analyzed 19 plasma NMR measures of FAs from 239,268 participants in the UKB. Although previous GWAS of FA traits in the UKB reported many loci, we identified approximately 90% more loci with a doubled sample size.[29,32,33] In addition, we compared our results with all previous GWAS of FAs-related traits to identify novel loci, including the second-largest published GWAS to date, which included 136,016 participants from 33 cohorts.[37] We calculated the omega-3/omega-6 and PUFA/SFA ratios for GWAS for the first time. Although the omega-6 to omega-3 ratio is commonly used in studies, the omega-3/omega-6 ratio may better capture the benefits of omega-3. This is particularly relevant given the ongoing debate over the potential harmful or beneficial effects of omega-6 PUFAs.[72] Our large GWAS of FAs showed that the phenotypic variance explained by all SNPs ranged from 5–19%, while heritability estimates from twin studies were approximately 25–62%.[14] These results suggest that future studies with

rare or structural variants from sequencing and more diverse ancestry groups could be valuable for

identifying additional loci for FA traits.

Variants in the *FADS* gene cluster are well-known for modifying polyunsaturated fatty acid

desaturation, but the underlying molecular mechanisms require investigation. Using OPERA, we

identified the potential causal variant rs174564 in *FADS1*, which is associated with the *MYRF* gene

and the methylation site cg01825921. The *LDLR* gene variant rs72658867 was linked to histone

modification (19:11105519:11214483) and chromatin accessibility (264429), impacting lipid

metabolism and cardiovascular health.[73] The variant rs149903077 in the novel *DGKZ* locus has

been associated with the nearby gene *NR1H3*, chromatin accessibility, histone modifications, and

DNA methylation, highlighting their combined roles in nuclear receptor regulation, lipid

metabolism, and immune responses.[74] The novel *GSTTP1* locus, or nearby genes on chromosome

22, overlapped with all six molecular phenotypes and has been linked to key biological processes

such as detoxification, cancer susceptibility, and cellular responses to oxidative stress.[75]

Gene set analysis findings highlight biological pathways underlying FA loci, implicating

lipid homeostasis, transport, and metabolism, and providing genetic support for the current

understanding of fatty acid regulation.[76] Our previous study suggested that lower omega-6% may

reduce alcohol consumption, with the secondary alcohol metabolism pathway potentially

explaining this effect on alcohol-related behaviors.[6] In model 3, which adjusts for lipoprotein lipid

levels, fatty acid metabolic and biosynthetic processes were significantly more enriched in the

gene set analysis of GWAS of total PUFAs. The investigation of the disparities between models 2

and 3 suggests that lipoprotein-related biomarkers play a critical role in FA loci. Future studies are

needed to thoroughly dissect these roles, and further analyses, such as Mendelian randomization,

should properly infer results using genetic variants with or without adjustment for lipoprotein-

related biomarkers.[78]

We investigated the sex-specific genetic architecture of FA traits. A novel locus,

KRT18P55, was identified in the GWAS for females, and previous research indicates that this

locus is highly expressed in patients with gastric cancer.[79] Notably, only one X-chromosomal locus

was identified in the male-only GWAS for omega-3%, tagged by the lead variants rs147828433

(closest protein-coding gene: *ACOT9*). A study on *ACOT9* in mice suggests that it regulates both

fatty acid and amino acid metabolism in mitochondria.[80] For the female-only GWAS, the

heritability was higher and larger numbers of loci were identified. Our results highlight the

importance of tracking sex differences in genetics and may motivate future studies on gene-sex

interactions. We found higher plasma PUFA levels in females, consistent with previous studies,

which were influenced by genetic effects, sex hormones, and conversion rates in FA metabolism.[9]

Randomized controlled trials show sex- and race-specific differences in the benefits of fish oil

supplementation and omega-3 PUFAs for preventing cardiovascular events and cognitive

decline.[81]

By performing ancestry-specific and sex-specific GWAS in non-EUR samples, we

identified additional novel loci, suggesting ancestry-specific genetic architecture of FA traits. In

male CSA participants, the novel locus *EDN1*, associated with omega-6 PUFA traits, encodes the

protein endothelin 1, which has been linked to cardiovascular events and prognosis.[82] Variants in

VPS39, associated with omega-6 PUFAs in the CSA population, have been previously identified

as important regulators of myoblast differentiation and muscle glucose uptake in patients with type

2 diabetes.[83] Besides these ancestry-specific signals, we also found several loci identified from

large EUR GWAS were transferable to other ancestry groups, including *FADS2*, *ZNF259*, *MYRF*,

APOA5, *GCKR*, *APOE*, and other loci. We found significantly fewer loci in the other five non-EUR ancestry GWAS due to small sample sizes. These results suggest that future studies with larger and more diverse ancestry samples are needed to identify more loci and confirm their consistency across populations.

To the best of our knowledge, our study is the most comprehensive GWAS on FA traits in a very large cohort. First, this is the first study to integrate six types of xQTL data with FA GWAS to explore the possible molecular mechanisms of FA-associated genetic variants. Second, we used a large number of participants of EUR ancestry with plasma NMR measures for 19 FA traits and included participants from five other ancestry groups. Third, the inclusion of the omega-3/omega-6 ratio in the GWAS provides better insights into the benefits of omega-3 PUFAs. Fourth, our sex-specific GWAS on EUR and non-EUR populations, as well as identified X-chromosomal loci, uncover sex differences in FA genetic basis. Fifth, we comprehensively compared our findings to all previous GWAS of FAs-related traits. Detailed information on all novel and known loci has been provided (Tables S5 and S7), which offers a good resource for researchers to further explore FAs-related loci. Finally, we adjusted for various covariates across three models, with a particular focus on genetic architecture adjusted for lipoprotein metabolism.

The study has limitations. The number of participants from non-EUR populations was low, and future studies with larger sample sizes are necessary. While we explored the molecular mechanisms of FA loci, we are eager to extend OPERA analysis to other tissues, particularly the liver, and even specific cell types, to identify cell type-specific disease mechanisms.

In conclusion, our findings reveal novel genetic loci and provide the first evidence of molecular mechanisms underlying FA-relevant variants. These insights could aid patient

443   stratification for precision nutrition and the identification of novel therapeutic targets for FAs-

444   related diseases.

Data availability

The full summary statistics for GWAS of fatty acids will be publicly available in the GWAS Catalog database (https://www.ebi.ac.uk/gwas/). The blood eQTL data of eQTLGen Consortium used in the analyses were downloaded from https://molgenis26.gcc.rug.nl/downloads/eqtlgen/cis-eqtl/SMR_formatted/cis-eQTL- https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1SMR_20191212.tar.gz. UKBB pQTL data are available at https://metabolomips.org/ukbbpgwas/. The mQTL data are available for download from https://zenodo.org/records/7951839/files/LBC_BSGS_meta.tar.gz?download=1. Blood sQTL data can be downloaded at https://yanglab.westlake.edu.cn/data/SMR/GTEx_V8_cis_sqtl_summary/sQTL_Whole_Blood.zip. The hQTL data can be assessed from http://ftp.ebi.ac.uk/pub/databases/blueprint/blueprint_Epivar/qtl_as/QTL_RESULTS/. Summary statistics of caQTL can be found at https://zenodo.org/records/1405945/files/.

Acknowledgments

This research was approved by the University of Georgia Institutional Review Board and the UK Biobank consortium (application no. 48818). This work was funded by the University of Georgia Research Foundation and by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM143060. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author contributions

467   Y.S. and K.Y. designed the study. Y.S. and H.X. performed analyses. Y.S. and K.Y. drafted the

468   manuscript. All authors contributed to the review and critical revision of the manuscript.

469   **Declaration of interests**

470   The authors declare no competing interests.

References

1.   Worthmann, A., Ridder, J., Piel, S.Y.L., Evangelakos, I., Musfeldt, M., Voss, H.,
O'Farrell, M., Fischer, A.W., Adak, S., Sundd, M., et al. (2024). Fatty acid synthesis
suppresses dietary polyunsaturated fatty acid use. Nat Commun *15*, 45. 10.1038/s41467-
023-44364-y.
2.   Baum, S.J., Kris-Etherton, P.M., Willett, W.C., Lichtenstein, A.H., Rudel, L.L., Maki,
K.C., Whelan, J., Ramsden, C.E., and Block, R.C. (2012). Fatty acids in cardiovascular
health and disease: a comprehensive update. J Clin Lipidol *6*, 216-234.
10.1016/j.jacl.2012.04.077.
3.   Astrup, A., Magkos, F., Bier, D.M., Brenna, J.T., de Oliveira Otto, M.C., Hill, J.O., King,
J.C., Mente, A., Ordovas, J.M., Volek, J.S., et al. (2020). Saturated Fats and Health: A
Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art
Review. J Am Coll Cardiol *76*, 844-857. 10.1016/j.jacc.2020.05.077.
4.   Scorletti, E., and Byrne, C.D. (2013). Omega-3 fatty acids, hepatic lipid metabolism, and
nonalcoholic fatty liver disease. Annu Rev Nutr *33*, 231-248. 10.1146/annurev-nutr-
071812-161230.
5.   Zhang, Y., Sun, Y., Yu, Q., Song, S., Brenna, J.T., Shen, Y., and Ye, K. (2024). Higher
ratio of plasma omega-6/omega-3 fatty acids is associated with greater risk of all-cause,
cancer, and cardiovascular mortality: A population-based cohort study in UK Biobank.
Elife *12*. 10.7554/eLife.90132.
6.   Xu, H., Sun, Y., Francis, M., Cheng, C.F., Modulla, N.T.R., Brenna, J.T., Chiang,
C.W.K., and Ye, K. (2023). Shared genetic basis informs the roles of polyunsaturated
fatty acids in brain disorders. medRxiv. 10.1101/2023.10.03.23296500.
7.   Sun, Y., Chatterjee, R., Ronanki, A., and Ye, K. (2022). Circulating Polyunsaturated
Fatty Acids and COVID-19: A Prospective Cohort Study and Mendelian Randomization
Analysis. Front Med (Lausanne) *9*, 923746. 10.3389/fmed.2022.923746.
8.   Hodson, L., Skeaff, C.M., and Fielding, B.A. (2008). Fatty acid composition of adipose
tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res
47, 348-380. 10.1016/j.plipres.2008.03.003.
9.   Decsi, T., and Kennedy, K. (2011). Sex-specific differences in essential fatty acid
metabolism. Am J Clin Nutr *94*, 1914S-1919S. 10.3945/ajcn.110.000893.
10.   Mathias, R.A., Pani, V., and Chilton, F.H. (2014). Genetic Variants in the FADS Gene:
Implications for Dietary Recommendations for Fatty Acid Intake. Curr Nutr Rep *3*, 139-
148. 10.1007/s13668-014-0079-1.
11.   Zhuang, P., Liu, X., Li, Y., Wu, Y., Li, H., Wan, X., Zhang, L., Xu, C., Jiao, J., and
Zhang, Y. (2023). Circulating fatty acids, genetic risk, and incident coronary artery
disease: A prospective, longitudinal cohort study. Sci Adv *9*, eadf9037.
10.1126/sciadv.adf9037.
12.   Tanaka, T., Shen, J., Abecasis, G.R., Kisialiou, A., Ordovas, J.M., Guralnik, J.M.,
Singleton, A., Bandinelli, S., Cherubini, A., Arnett, D., et al. (2009). Genome-wide
association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS
Genet *5*, e1000338. 10.1371/journal.pgen.1000338.
13.   Lemaitre, R.N., Tanaka, T., Tang, W., Manichaikul, A., Foy, M., Kabagambe, E.K.,
Nettleton, J.A., King, I.B., Weng, L.C., Bhattacharya, S., et al. (2011). Genetic loci
associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide

association studies from the CHARGE Consortium. PLoS Genet *7*, e1002193.
10.1371/journal.pgen.1002193.

14.   Kettunen, J., Tukiainen, T., Sarin, A.P., Ortega-Alonso, A., Tikkanen, E., Lyytikainen,
L.P., Kangas, A.J., Soininen, P., Wurtz, P., Silander, K., et al. (2012). Genome-wide
association study identifies multiple loci influencing human serum metabolite levels. Nat
Genet *44*, 269-276. 10.1038/ng.1073.

15.   Wu, J.H., Lemaitre, R.N., Manichaikul, A., Guan, W., Tanaka, T., Foy, M., Kabagambe,
E.K., Djousse, L., Siscovick, D., Fretts, A.M., et al. (2013). Genome-wide association
study identifies novel loci associated with concentrations of four plasma phospholipid
fatty acids in the de novo lipogenesis pathway: results from the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) consortium. Circ Cardiovasc
Genet *6*, 171-183. 10.1161/CIRCGENETICS.112.964619.

16.   Guan, W., Steffen, B.T., Lemaitre, R.N., Wu, J.H.Y., Tanaka, T., Manichaikul, A., Foy,
M., Rich, S.S., Wang, L., Nettleton, J.A., et al. (2014). Genome-wide association study of
plasma N6 polyunsaturated fatty acids within the cohorts for heart and aging research in
genomic epidemiology consortium. Circ Cardiovasc Genet *7*, 321-331.
10.1161/CIRCGENETICS.113.000208.

17.   Lemaitre, R.N., King, I.B., Kabagambe, E.K., Wu, J.H., McKnight, B., Manichaikul, A.,
Guan, W., Sun, Q., Chasman, D.I., Foy, M., et al. (2015). Genetic loci associated with
circulating levels of very long-chain saturated fatty acids. J Lipid Res *56*, 176-184.
10.1194/jlr.M052456.

18.   Tintle, N.L., Pottala, J.V., Lacey, S., Ramachandran, V., Westra, J., Rogers, A., Clark, J.,
Olthoff, B., Larson, M., Harris, W., and Shearer, G.C. (2015). A genome-wide
association study of saturated, mono- and polyunsaturated red blood cell fatty acids in the
Framingham Heart Offspring Study. Prostaglandins Leukot Essent Fatty Acids *94*, 65-72.
10.1016/j.plefa.2014.11.007.

19.   Dorajoo, R., Sun, Y., Han, Y., Ke, T., Burger, A., Chang, X., Low, H.Q., Guan, W.,
Lemaitre, R.N., Khor, C.C., et al. (2015). A genome-wide association study of n-3 and n-
6 plasma fatty acids in a Singaporean Chinese population. Genes Nutr *10*, 53.
10.1007/s12263-015-0502-2.

20.   Hu, Y., Li, H., Lu, L., Manichaikul, A., Zhu, J., Chen, Y.D., Sun, L., Liang, S.,
Siscovick, D.S., Steffen, L.M., et al. (2016). Genome-wide meta-analyses identify novel
loci associated with n-3 and n-6 polyunsaturated fatty acid levels in Chinese and
European-ancestry populations. Hum Mol Genet *25*, 1215-1224. 10.1093/hmg/ddw002.

21.   Kettunen, J., Demirkan, A., Wurtz, P., Draisma, H.H., Haller, T., Rawal, R., Vaarhorst,
A., Kangas, A.J., Lyytikainen, L.P., Pirinen, M., et al. (2016). Genome-wide study for
circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. Nat
Commun *7*, 11122. 10.1038/ncomms11122.

22.   Kalsbeek, A., Veenstra, J., Westra, J., Disselkoen, C., Koch, K., McKenzie, K.A., O'Bott,
J., Vander Woude, J., Fischer, K., Shearer, G.C., et al. (2018). A genome-wide
association study of red-blood cell fatty acids and ratios incorporating dietary covariates:
Framingham Heart Study Offspring Cohort. PLoS One *13*, e0194882.
10.1371/journal.pone.0194882.

23.   de Oliveira Otto, M.C., Lemaitre, R.N., Sun, Q., King, I.B., Wu, J.H.Y., Manichaikul, A.,
Rich, S.S., Tsai, M.Y., Chen, Y.D., Fornage, M., et al. (2018). Genome-wide association

meta-analysis of circulating odd-numbered chain saturated fatty acids: Results from the
CHARGE Consortium. PLoS One *13*, e0196951. 10.1371/journal.pone.0196951.

24. Marklund, M., Morris, A.P., Mahajan, A., Ingelsson, E., Lindgren, C.M., Lind, L., and
Riserus, U. (2018). Genome-Wide Association Studies of Estimated Fatty Acid
Desaturase Activity in Serum and Adipose Tissue in Elderly Individuals: Associations
with Insulin Sensitivity. Nutrients *10*. 10.3390/nu10111791.

25. Locke, A.E., Steinberg, K.M., Chiang, C.W.K., Service, S.K., Havulinna, A.S., Stell, L.,
Pirinen, M., Abel, H.J., Chiang, C.C., Fulton, R.S., et al. (2019). Exome sequencing of
Finnish isolates enhances rare-variant association power. Nature *572*, 323-328.
10.1038/s41586-019-1457-z.

26. Coltell, O., Sorli, J.V., Asensio, E.M., Barragan, R., Gonzalez, J.I., Gimenez-Alba, I.M.,
Zanon-Moreno, V., Estruch, R., Ramirez-Sabio, J.B., Pascual, E.C., et al. (2020).
Genome-Wide Association Study for Serum Omega-3 and Omega-6 Polyunsaturated
Fatty Acids: Exploratory Analysis of the Sex-Specific Effects and Dietary Modulation in
Mediterranean Subjects with Metabolic Syndrome. Nutrients *12*. 10.3390/nu12020310.

27. Riveros-Mckay, F., Oliver-Williams, C., Karthikeyan, S., Walter, K., Kundu, K.,
Ouwehand, W.H., Roberts, D., Di Angelantonio, E., Soranzo, N., Danesh, J., et al.
(2020). The influence of rare variants in circulating metabolic biomarkers. PLoS Genet
16, e1008605. 10.1371/journal.pgen.1008605.

28. Li-Gao, R., Hughes, D.A., van Klinken, J.B., de Mutsert, R., Rosendaal, F.R., Mook-
Kanamori, D.O., Timpson, N.J., and Willems van Dijk, K. (2021). Genetic Studies of
Metabolomics Change After a Liquid Meal Illuminate Novel Pathways for Glucose and
Lipid Metabolism. Diabetes *70*, 2932-2946. 10.2337/db21-0397.

29. Richardson, T.G., Leyden, G.M., Wang, Q., Bell, J.A., Elsworth, B., Davey Smith, G.,
and Holmes, M.V. (2022). Characterising metabolomic signatures of lipid-modifying
therapies through drug target mendelian randomisation. PLoS Biol *20*, e3001547.
10.1371/journal.pbio.3001547.

30. Yin, X., Chan, L.S., Bose, D., Jackson, A.U., VandeHaar, P., Locke, A.E., Fuchsberger,
C., Stringham, H.M., Welch, R., Yu, K., et al. (2022). Genome-wide association studies
of metabolites in Finnish men identify disease-relevant loci. Nat Commun *13*, 1644.
10.1038/s41467-022-29143-5.

31. Montasser, M.E., Aslibekyan, S., Srinivasasainagendra, V., Tiwari, H.K., Patki, A.,
Bagheri, M., Kind, T., Barupal, D.K., Fan, S., Perry, J., et al. (2022). An Amish founder
population reveals rare-population genetic determinants of the human lipidome. Commun
Biol *5*, 334. 10.1038/s42003-022-03291-2.

32. Francis, M., Sun, Y., Xu, H., Brenna, J.T., and Ye, K. (2022). Fifty-one novel and
replicated GWAS loci for polyunsaturated and monounsaturated fatty acids in 124,024
Europeans. medRxiv, 2022.2005.2027.22275343. 10.1101/2022.05.27.22275343.

33. Borges, M.C., Haycock, P.C., Zheng, J., Hemani, G., Holmes, M.V., Davey Smith, G.,
Hingorani, A.D., and Lawlor, D.A. (2022). Role of circulating polyunsaturated fatty acids
on cardiovascular diseases risk: analysis using Mendelian randomization and fatty acid
genetic association data from over 114,000 UK Biobank participants. BMC Med *20*, 210.
10.1186/s12916-022-02399-w.

34. Liu, C., Wang, Z., Hui, Q., Chiang, Y., Chen, J., Brijkumar, J., Edwards, J.A., Ordonez,
C.E., Dudgeon, M.R., Sunpath, H., et al. (2022). Crosstalk between Host Genome and

Metabolome among People with HIV in South Africa. Metabolites *12*.
10.3390/metabo12070624.

35. Davyson, E., Shen, X., Gadd, D.A., Bernabeu, E., Hillary, R.F., McCartney, D.L.,
Adams, M., Marioni, R., and McIntosh, A.M. (2023). Metabolomic Investigation of
Major Depressive Disorder Identifies a Potentially Causal Association With
Polyunsaturated Fatty Acids. Biol Psychiatry *94*, 630-639.
10.1016/j.biopsych.2023.01.027.

36. Fuller, H., Iles, M.M., Moore, J.B., and Zulyniak, M.A. (2023). Metabolic drivers of
dysglycemia in pregnancy: ethnic-specific GWAS of 146 metabolites and 1-sample
Mendelian randomization analyses in a UK multi-ethnic birth cohort. Front Endocrinol
(Lausanne) *14*, 1157416. 10.3389/fendo.2023.1157416.

37. Karjalainen, M.K., Karthikeyan, S., Oliver-Williams, C., Sliz, E., Allara, E., Fung, W.T.,
Surendran, P., Zhang, W., Jousilahti, P., Kristiansson, K., et al. (2024). Genome-wide
characterization of circulating metabolic biomarkers. Nature *628*, 130-138.
10.1038/s41586-024-07148-y.

38. Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott,
P., Green, J., Landray, M., et al. (2015). UK biobank: an open access resource for
identifying the causes of a wide range of complex diseases of middle and old age. PLoS
Med *12*, e1001779. 10.1371/journal.pmed.1001779.

39. Pan-ancestry genetic analysis of the UK Biobank. https://pan.ukbb.broadinstitute.org/.

40. Julkunen, H., Cichonska, A., Slagboom, P.E., Wurtz, P., and Nightingale Health,
U.K.B.I. (2021). Metabolic biomarker profiling for identification of susceptibility to
severe pneumonia and COVID-19 in the general population. Elife *10*.
10.7554/eLife.63033.

41. McCaw, Z.R., Lane, J.M., Saxena, R., Redline, S., and Lin, X. (2020). Operating
characteristics of the rank-based inverse normal transformation for quantitative trait
analysis in genome-wide association studies. Biometrics *76*, 1262-1272.
10.1111/biom.13214.

42. Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A.,
Vukcevic, D., Delaneau, O., O'Connell, J., et al. (2018). The UK Biobank resource with
deep phenotyping and genomic data. Nature *562*, 203-209. 10.1038/s41586-018-0579-z.

43. Jiang, L., Zheng, Z., Qi, T., Kemper, K.E., Wray, N.R., Visscher, P.M., and Yang, J.
(2019). A resource-efficient tool for mixed model association analysis of large-scale data.
Nat Genet *51*, 1749-1755. 10.1038/s41588-019-0530-8.

44. International HapMap, C., Altshuler, D.M., Gibbs, R.A., Peltonen, L., Altshuler, D.M.,
Gibbs, R.A., Peltonen, L., Dermitzakis, E., Schaffner, S.F., Yu, F., et al. (2010).
Integrating common and rare genetic variation in diverse human populations. Nature *467*,
52-58. 10.1038/nature09298.

45. Yang, J., Zaitlen, N.A., Goddard, M.E., Visscher, P.M., and Price, A.L. (2014).
Advantages and pitfalls in the application of mixed-model association methods. Nat
Genet *46*, 100-106. 10.1038/ng.2876.

46. Jordan, H., Roderick, P., and Martin, D. (2004). The Index of Multiple Deprivation 2000
and accessibility effects on health. J Epidemiol Community Health *58*, 250-257.
10.1136/jech.2003.013011.

47. Cleland, C., Ferguson, S., Ellis, G., and Hunter, R.F. (2018). Validity of the International
Physical Activity Questionnaire (IPAQ) for assessing moderate-to-vigorous physical

651    activity and sedentary behaviour of older adults in the United Kingdom. BMC Med Res
652    Methodol *18*, 176. 10.1186/s12874-018-0642-3.
653  48. Welter, D., MacArthur, J., Morales, J., Burdett, T., Hall, P., Junkins, H., Klemm, A.,
654    Flicek, P., Manolio, T., Hindorff, L., and Parkinson, H. (2014). The NHGRI GWAS
655    Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res *42*, D1001-
656    1006. 10.1093/nar/gkt1229.
657  49. Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter, D.J.,
658    McCarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., et al. (2009). Finding the
659    missing heritability of complex diseases. Nature *461*, 747-753. 10.1038/nature08494.
660  50. Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller,
661    J., Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK: a tool set for
662    whole-genome association and population-based linkage analyses. Am J Hum Genet *81*,
663    559-575. 10.1086/519795.
664  51. McLaren, W., Pritchard, B., Rios, D., Chen, Y., Flicek, P., and Cunningham, F. (2010).
665    Deriving the consequences of genomic variants with the Ensembl API and SNP Effect
666    Predictor. Bioinformatics *26*, 2069-2070. 10.1093/bioinformatics/btq330.
667  52. Bulik-Sullivan, B.K., Loh, P.R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia
668    Working Group of the Psychiatric Genomics, C., Patterson, N., Daly, M.J., Price, A.L.,
669    and Neale, B.M. (2015). LD Score regression distinguishes confounding from
670    polygenicity in genome-wide association studies. Nat Genet *47*, 291-295.
671    10.1038/ng.3211.
672  53. Bulik-Sullivan, B., Finucane, H.K., Anttila, V., Gusev, A., Day, F.R., Loh, P.R.,
673    ReproGen, C., Psychiatric Genomics, C., Genetic Consortium for Anorexia Nervosa of
674    the Wellcome Trust Case Control, C., Duncan, L., et al. (2015). An atlas of genetic
675    correlations across human diseases and traits. Nat Genet *47*, 1236-1241.
676    10.1038/ng.3406.
677  54. Weissbrod, O., Hormozdiari, F., Benner, C., Cui, R., Ulirsch, J., Gazal, S., Schoech, A.P.,
678    van de Geijn, B., Reshef, Y., Marquez-Luna, C., et al. (2020). Functionally informed
679    fine-mapping and polygenic localization of complex trait heritability. Nat Genet *52*,
680    1355-1363. 10.1038/s41588-020-00735-5.
681  55. Loh, P.R., Kichaev, G., Gazal, S., Schoech, A.P., and Price, A.L. (2018). Mixed-model
682    association for biobank-scale datasets. Nat Genet *50*, 906-908. 10.1038/s41588-018-
683    0144-6.
684  56. Foley, C.N., Staley, J.R., Breen, P.G., Sun, B.B., Kirk, P.D.W., Burgess, S., and Howson,
685    J.M.M. (2021). A fast and efficient colocalization algorithm for identifying shared
686    genetic risk factors across multiple traits. Nat Commun *12*, 764. 10.1038/s41467-020-
687    20885-8.
688  57. Wang, G., Sarkar, A., Carbonetto, P., and Stephens, M. (2020). A simple new approach
689    to variable selection in regression, with application to genetic fine mapping. J R Stat Soc
690    Series B Stat Methodol *82*, 1273-1300. 10.1111/rssb.12388.
691  58. Watanabe, K., Taskesen, E., van Bochoven, A., and Posthuma, D. (2017). Functional
692    mapping and annotation of genetic associations with FUMA. Nat Commun *8*, 1826.
693    10.1038/s41467-017-01261-5.
694  59. Lee, S.H., Wray, N.R., Goddard, M.E., and Visscher, P.M. (2011). Estimating missing
695    heritability for disease from genome-wide association studies. Am J Hum Genet *88*, 294-
696    305. 10.1016/j.ajhg.2011.02.002.

60.   Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., and
Mesirov, J.P. (2011). Molecular signatures database (MSigDB) 3.0. Bioinformatics *27*,
1739-1740. 10.1093/bioinformatics/btr260.

61.   Wu, Y., Qi, T., Wray, N.R., Visscher, P.M., Zeng, J., and Yang, J. (2023). Joint analysis
of GWAS and multi-omics QTL summary statistics reveals a large fraction of GWAS
signals shared with molecular phenotypes. Cell Genom *3*, 100344.
10.1016/j.xgen.2023.100344.

62.   Vosa, U., Claringbould, A., Westra, H.J., Bonder, M.J., Deelen, P., Zeng, B., Kirsten, H.,
Saha, A., Kreuzhuber, R., Yazar, S., et al. (2021). Large-scale cis- and trans-eQTL
analyses identify thousands of genetic loci and polygenic scores that regulate blood gene
expression. Nat Genet *53*, 1300-1310. 10.1038/s41588-021-00913-z.

63.   Sun, B.B., Chiou, J., Traylor, M., Benner, C., Hsu, Y.H., Richardson, T.G., Surendran,
P., Mahajan, A., Robins, C., Vasquez-Grinnell, S.G., et al. (2023). Plasma proteomic
associations with genetics and health in the UK Biobank. Nature *622*, 329-338.
10.1038/s41586-023-06592-6.

64.   Wu, Y., Zeng, J., Zhang, F., Zhu, Z., Qi, T., Zheng, Z., Lloyd-Jones, L.R., Marioni, R.E.,
Martin, N.G., Montgomery, G.W., et al. (2018). Integrative analysis of omics summary
data reveals putative mechanisms underlying complex traits. Nat Commun *9*, 918.
10.1038/s41467-018-03371-0.

65.   McRae, A.F., Marioni, R.E., Shah, S., Yang, J., Powell, J.E., Harris, S.E., Gibson, J.,
Henders, A.K., Bowdler, L., Painter, J.N., et al. (2018). Identification of 55,000
Replicated DNA Methylation QTL. Sci Rep *8*, 17605. 10.1038/s41598-018-35871-w.

66.   Consortium, G.T. (2020). The GTEx Consortium atlas of genetic regulatory effects
across human tissues. Science *369*, 1318-1330. 10.1126/science.aaz1776.

67.   Chen, L., Ge, B., Casale, F.P., Vasquez, L., Kwan, T., Garrido-Martin, D., Watt, S., Yan,
Y., Kundu, K., Ecker, S., et al. (2016). Genetic Drivers of Epigenetic and Transcriptional
Variation in Human Immune Cells. Cell *167*, 1398-1414 e1324.
10.1016/j.cell.2016.10.026.

68.   Kumasaka, N., Knights, A.J., and Gaffney, D.J. (2019). High-resolution genetic mapping
of putative causal interactions between regions of open chromatin. Nat Genet *51*, 128-
137. 10.1038/s41588-018-0278-6.

69.   Goldstein, J.L., and Brown, M.S. (2009). The LDL receptor. Arterioscler Thromb Vasc
Biol *29*, 431-438. 10.1161/ATVBAHA.108.179564.

70.   Naik, A., Kosir, R., and Rozman, D. (2013). Genomic aspects of NAFLD pathogenesis.
Genomics *102*, 84-95. 10.1016/j.ygeno.2013.03.007.

71.   Gao, L., Tse, S.W., Conrad, C., and Andreadis, A. (2005). Saitohin, which is nested in
the tau locus and confers allele-specific susceptibility to several neurodegenerative
diseases, interacts with peroxiredoxin 6. J Biol Chem *280*, 39268-39272.
10.1074/jbc.M506116200.

72.   Schulze, M.B., Minihane, A.M., Saleh, R.N.M., and Riserus, U. (2020). Intake and
metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications
for cardiometabolic diseases. Lancet Diabetes Endocrinol *8*, 915-930. 10.1016/S2213-
8587(20)30148-0.

73.   Gretarsdottir, S., Helgason, H., Helgadottir, A., Sigurdsson, A., Thorleifsson, G.,
Magnusdottir, A., Oddsson, A., Steinthorsdottir, V., Rafnar, T., de Graaf, J., et al. (2015).
A Splice Region Variant in LDLR Lowers Non-high Density Lipoprotein Cholesterol and

Protects against Coronary Artery Disease. PLoS Genet *11*, e1005379.
10.1371/journal.pgen.1005379.

74. Raben, D.M., and Tu-Sekine, B. (2008). Nuclear diacylglycerol kinases: regulation and
roles. Front Biosci *13*, 590-597. 10.2741/2704.

75. Sadafi, S., Choubsaz, P., Kazemeini, S.M.M., Imani, M.M., and Sadeghi, M. (2024).
Glutathione S-transferase theta 1 (GSTT1) deletion polymorphism and susceptibility to
head and neck carcinoma: a systematic review with five analyses. BMC Cancer *24*, 885.
10.1186/s12885-024-12618-7.

76. Li, H., Herrmann, T., Seessle, J., Liebisch, G., Merle, U., Stremmel, W., and Chamulitrat,
W. (2022). Role of fatty acid transport protein 4 in metabolic tissues: insights into obesity
and fatty liver disease. Biosci Rep *42*. 10.1042/BSR20211854.

77. Sundaram, M., and Yao, Z. (2010). Recent progress in understanding protein and lipid
factors affecting hepatic VLDL assembly and secretion. Nutr Metab (Lond) *7*, 35.
10.1186/1743-7075-7-35.

78. Pingault, J.B., O'Reilly, P.F., Schoeler, T., Ploubidis, G.B., Rijsdijk, F., and Dudbridge,
F. (2018). Using genetic data to strengthen causal inference in observational research.
Nat Rev Genet *19*, 566-580. 10.1038/s41576-018-0020-3.

79. Tayefeh-Gholami, S., Ghanbari, M., Aghazadeh, A., Rajabi, A., Saber, A., Hussen, B.M.,
Farsad-Akhtar, N., and Safaralizadeh, R. (2022). Prognostic Value of LncRNA
KRT18P55 in Patients with Intestinal Type of Gastric Cancer. J Gastrointest Cancer *53*,
1014-1019. 10.1007/s12029-021-00744-5.

80. Tillander, V., Arvidsson Nordstrom, E., Reilly, J., Strozyk, M., Van Veldhoven, P.P.,
Hunt, M.C., and Alexson, S.E. (2014). Acyl-CoA thioesterase 9 (ACOT9) in mouse may
provide a novel link between fatty acid and amino acid metabolism in mitochondria. Cell
Mol Life Sci *71*, 933-948. 10.1007/s00018-013-1422-1.

81. Welty, F.K., Daher, R., and Garelnabi, M. (2024). Fish and Omega-3 Fatty Acids: Sex
and Racial Differences in Cardiovascular Outcomes and Cognitive Function. Arterioscler
Thromb Vasc Biol *44*, 89-107. 10.1161/ATVBAHA.122.318125.

82. Jankowich, M., and Choudhary, G. (2020). Endothelin-1 levels and cardiovascular
events. Trends Cardiovasc Med *30*, 1-8. 10.1016/j.tcm.2019.01.007.

83. Davegardh, C., Sall, J., Benrick, A., Broholm, C., Volkov, P., Perfilyev, A., Henriksen,
T.I., Wu, Y., Hjort, L., Brons, C., et al. (2021). VPS39-deficiency observed in type 2
diabetes impairs muscle stem cell differentiation via altered autophagy and epigenetics.
Nat Commun *12*, 2431. 10.1038/s41467-021-22068-5.

Figure Captions

Main Figures

Figure 1. Manhattan plot of the genome-wide association studies for the absolute concentration of total polyunsaturated fatty acids. The association of each variant with polyunsaturated fatty acids was obtained from genome-wide association studies using models 2 (A) and 3 (B). A variant with a P-value below 5×10^{-8} was considered statistically significant. The nearest gene at each genome-wide significant locus is annotated, in black for known loci and in red for novel loci.

Figure 2. Miami plot of the absolute concentration of total polyunsaturated fatty acids from genome-wide association studies using model 2. The top panel shows the GWAS results in females, while the bottom panel shows the GWAS results in males. The $-\log_{10}(P\text{-value})$ is plotted on the y-axis and chromosomal location is plotted on the x-axis. The genome-wide significance threshold (P-value $< 5 \times 10^{-8}$) is indicated by the red dashed line. The nearest gene at each genome-wide significant locus is annotated, in black for known loci and in red for novel loci.

Figure 3. Pathway analysis of polyunsaturated fatty acids from genome-wide association studies using model 2. Treemap depicting significantly enriched pathways at an adjusted P-value threshold of 0.05. Gene ontology terms were clustered based on semantic similarity, with terms displayed as individual rectangles. The color indicates cluster membership, and thick border lines differentiate clusters. The size of each rectangle represents the enrichment significance, and the most significantly enriched term in each cluster is highlighted in white text as the representative term.

Figure 4. Number of loci for fatty acid traits associated with different molecular phenotype combinations. (A and B) The number of loci associated with 19 fatty acid traits and molecular quantitative trait loci (xQTLs) was determined based on genome-wide association studies using models 2 (A) and 3 (B). The loci numbers are based on significant OPERA association results that pass a posterior probability of association threshold of 0.9 and the multi-exposure heterogeneity in dependent instruments (HEIDI) test ($P_{HEIDI} > 0.01$). The x-axis represents the association hypotheses for different phenotype combinations, while the y-axis shows the number of loci associated with these combinations across 19 fatty acids. Each violin plot displays the distribution of loci numbers by width, with lines indicating the 25th percentile, median, and 75th percentile.

Figure 5. Prioritization of a locus near the *GSTT1/2/2B* genes for total fatty acids. The top track displays the $-\log_{10}(P\text{-value})$ of GWAS SNPs (gray dots) for total fatty acids. Red diamonds indicate OPERA marginal PPA for gene associations using eQTL data, while blue circles show OPERA marginal PPA for associations with DNA methylation, RNA splicing, histone modification, and chromatin accessibility, respectively. The bottom track presents 14 chromatin state annotations inferred from the 127 samples of the Roadmap Epigenomics Mapping Consortium.

Figure 1.

Figure 2.

Figure 3.

Figure 5.